DGAP-Adhoc: Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH

2021. december 15., szerda, 13:45





DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover


Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH


15-Dec-2021 / 13:45 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)

No. 596/2014 on market abuse, as amended

(Market Abuse Regulation - MAR)




Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH



Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today entered into an agreement with Canopy Growth Germany GmbH, based in St. Leon-Rot, Germany, to acquire C³ Cannabinoid Compound GmbH, based in Neumarkt, Germany, and its subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, Germany, THC Pharm GmbH The Health Concept, based in Frankfurt, Germany, and Spectrum Therapeutics Austria GmbH, based in Vienna, Austria. Upon completion of the transaction, Dermapharm AG will acquire 100.00 percent of the shares in the company, which specializes in the development, production and marketing of natural and synthetic active pharmaceutical ingredients based on cannabinoids. The purchase price is in the order of EUR 80 million plus possible performance-based limited purchase price components.



The closing of the transaction is subject to the approval of the antitrust authorities. The Management Board expects the transaction to be completed by the end of January 2022.




>End of the Ad hoc announcement<



Contact



Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

E-Mail: ir@dermapharm.com











15-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1258267





 
End of Announcement DGAP News Service




1258267  15-Dec-2021 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1258267&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.